Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-412: Pembrolizumab with concurrent chemoradiotherapy and maintenance vs chemoradiotherapy alone in locally advanced head and neck squamous cell carcinoma
jRCT2080223584Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), oropharyngeal squamous cell carcinoma (OPSCC), laryngeal squamous cell carcinoma (LSCC) and 2 more (2 arms), sponsored by Merck & Co. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)oropharyngeal squamous cell carcinoma (OPSCC)laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynxOral Mucosal Carcinoma
Beyond the preview
Go deeper on jRCT2080223584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223584.